Eisbach Bio is the winner of the BIO-Europe 2019 Startup Slam in Hamburg. The Munich-based start-up is developing novel medicines that target chromatin regulatory mechanisms essential to tumors.
Ten short-listed life sciences startups pitched to an expert judging panel at the sixth Startup Slam competition at the partnering conference BIO-EuropeT in Hamburg. Eisbach Bio, founded in 2019, is a spin-off of the Biomedical Centre Munich of the Ludwig-Maximilians-Universität München (LMU) and develops novel drugs that successfully target molecular vulnerabilities arising in cancer genomes.
BioM has been supporting the Eisbach Bio team for quite some time with its comprehensive offer for life science founders.
We are very grateful for the helpful contacts and coaching by BioM during the implementation of our transformative new oncology approach. Eisbach emerged from local excellence in epigenetics and the long-term support of the LMU, the TUM (Technical University Munich), the Bavarian Government and the local biotech scene, which BioM has significantly shaped and driven," says Prof. Andreas Ladurner, founder and CSO of Eisbach Bio.
Prof. Andreas Ladurner receives a complimentary registration to BIO-Europe Spring 2020 in Paris, plus access to a top-tier mentoring program with industry experts from Johnson & Johnson Innovation, sponsor of the start-up slam competition.
This year's line-up of innovative startups included companies developing novel therapeutics for the treatment of cancer, osteoporosis, and vascular disease, as well as a company with a novel drug delivery platform, one developing a vaccine against the world's foremost bacterial pathogen, and one targeting the root causes of ageing.